108 related articles for article (PubMed ID: 12015746)
21. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
[TBL] [Abstract][Full Text] [Related]
23. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression.
Kumar-Singh S; Weyler J; Martin MJ; Vermeulen PB; Van Marck E
J Pathol; 1999 Sep; 189(1):72-8. PubMed ID: 10451491
[TBL] [Abstract][Full Text] [Related]
24. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
[TBL] [Abstract][Full Text] [Related]
25. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
[TBL] [Abstract][Full Text] [Related]
26. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
[TBL] [Abstract][Full Text] [Related]
27. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
[TBL] [Abstract][Full Text] [Related]
28. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
Kim SJ; Lee SJ; Sung HJ; Choi IK; Choi CW; Kim BS; Kim JS; Yu W; Hwang HS; Kim IS
Acta Haematol; 2008; 120(4):211-6. PubMed ID: 19153476
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
Mezger J; Lamerz R; Permanetter W
J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
[TBL] [Abstract][Full Text] [Related]
30. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Orui H; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Nakano T; Hasegawa S
Ann Surg Oncol; 2012 Dec; 19(13):4229-37. PubMed ID: 22825770
[TBL] [Abstract][Full Text] [Related]
31. Role of PCNA in differentiating between malignant mesothelioma and mesothelial hyperplasia: prognostic considerations.
Esposito V; Baldi A; De Luca A; Paciocco G; Gröger A; Sgaramella G; Claudio PP; Giordano GG; Baldi F; Caputi M; Kaiser H; Giordano A
Anticancer Res; 1997; 17(1B):601-4. PubMed ID: 9066586
[TBL] [Abstract][Full Text] [Related]
32. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
33. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
Yan TD; Boyer M; Tin MM; Wong D; Kennedy C; McLean J; Bannon PG; McCaughan BC
J Thorac Cardiovasc Surg; 2009 Sep; 138(3):619-24. PubMed ID: 19698846
[TBL] [Abstract][Full Text] [Related]
34. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
35. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions.
Shu J; Sun G; Liu H; Liu J
Acta Oncol; 2007; 46(7):1004-11. PubMed ID: 17917830
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
Gaspar MJ; De Miguel J; García Díaz JD; Díez M
Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
[TBL] [Abstract][Full Text] [Related]
38. Increased survivin mRNA in malignant pleural effusion is significantly correlated with survival.
Lan CC; Wu YK; Lee CH; Huang YC; Huang CY; Tsai YH; Huang SF; Tsao TC
Jpn J Clin Oncol; 2010 Mar; 40(3):234-40. PubMed ID: 19933689
[TBL] [Abstract][Full Text] [Related]
39. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
Mineo TC; Ambrogi V; Cufari ME; Pompeo E
Eur J Cardiothorac Surg; 2010 Sep; 38(3):245-52. PubMed ID: 20338775
[TBL] [Abstract][Full Text] [Related]
40. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
